Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population

Sponsor

Sohag University (Other)

Overall Status

Completed

CT.gov ID

NCT05070039

Collaborator

(none)

Enrollment

Location

Arm

Actual Duration (Months)

6.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Urothelial carcinoma is the ninth most common malignant neoplasm worldwide. nearly in all human tumors, actin filaments are involved in lamellopodia or cellular extensions. Cortactin is involved in fixing the actin assembly to enhance cellular penetration. Assessment of Cortactin expression in invasive and non-invasive urothelial carcinoma and recording any significant different expressions may have benefits in developing more effective anticancer chemotherapeutic agents.

Condition or Disease	Intervention/Treatment	Phase
Urothelial Carcinoma	Genetic: Expression of Cortactin anti body	N/A

Detailed Description

Bladder carcinoma is the 9th most prevalent cancer worldwide. Mostcases are diagnosed in men. Bladder carcinoma is categorized into three disticly different categories; non- muscle invasive, muscle invasive and metastatic bladder carcinoma. Vast majority of all bladder carcinomas are diagnosed as urothelial carcinoma (UC). Squamous cell carcinoma (SCC), adenocarcinoma and other rare types represent the remaining 10%. In Egypt, bladder carcinoma is ranked as the most prevalent cancer . The most important etiological causes for such disease in Egypt are festation by S. haematopium and Cigarette smoking. Cortactin is a 63-65 kDa protein, encoded by a gene located on 11q13. Cortactin activates and binds to Arp2/3 and stabilizes the branched Actin networks. Invadopodia are Actin-rich cellular protrusions, associated with enhanced proteolytic activities in the invasive regions of carcinomas. it is also incorporated in invadopodia, Cortactin expression is enhanced once or rapidly following secretions of transmembrane metalloproteinase, MT1-MMP. Extracellular matrix (ECM) proteolytic cleavage develops soon after secretion of MT1-MMP and Cortactin. increased secretion of Cortactin was studied in a lot of malignant tumors, including melanoma, mammary, pancreatic duct, hepatocellular and colorectal adenocarcinomas.

Study Design

Study Type:

Interventional

Actual Enrollment :

40 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

formalin fixed and paraffin embedded blocks of urinary bladder malignant neoplasms will be obtained and sectioned. from each block, one tissue section will be stained by H&E, other section will be stained immunohistochemically by anti Cortactin antibodies.formalin fixed and paraffin embedded blocks of urinary bladder malignant neoplasms will be obtained and sectioned. from each block, one tissue section will be stained by H&E, other section will be stained immunohistochemically by anti Cortactin antibodies.

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population

Actual Study Start Date :

Jul 1, 2021

Actual Primary Completion Date :

Dec 30, 2021

Actual Study Completion Date :

Jan 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Other: patients with invasive and non invasive urothelial carcinoma patients with urothelial carcinoma will be subjected to radical cystectomy or trans uretheral resection of the tumor, specimens will be sent to the pathology lab. to be examined.	Genetic: Expression of Cortactin anti body assessment of Cortactin immunohistochemical expression in invasive and non-invasive urothelial carcinoma.

Arm

Intervention/Treatment

Other: patients with invasive and non invasive urothelial carcinoma

patients with urothelial carcinoma will be subjected to radical cystectomy or trans uretheral resection of the tumor, specimens will be sent to the pathology lab. to be examined.

Genetic: Expression of Cortactin anti body

assessment of Cortactin immunohistochemical expression in invasive and non-invasive urothelial carcinoma.

Outcome Measures

Primary Outcome Measures

Assessment and correlating Cortactin expression in invasive and non-invasive urothelial carcinoma. [6 months]
immunohistochemical staining of tumor sections and correlating the immuno-expresion of Cortactin to different tumor parameters as tumor grade, stage and status of lymph nodes involved, inorder to detect the prognostic role of Cortactin in urothelial carcinoma.

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

patients with primary urinary bladder carcinoma.

Exclusion Criteria:

patients received chemotherapeutic agents.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Maisa Hashem Mohammed	Sohag		Egypt	82524

Sponsors and Collaborators

Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Maisa Hashem Mohammed, lecturer of pathology, Sohag University

ClinicalTrials.gov Identifier:

NCT05070039

Other Study ID Numbers:

Soh-Med-21-09-44

First Posted:

Oct 6, 2021

Last Update Posted:

Jul 15, 2022

Last Verified:

Jul 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Maisa Hashem Mohammed, lecturer of pathology, Sohag University

Cortactin

Urothelial carcinoma

Additional relevant MeSH terms:

Carcinoma

Carcinoma, Transitional Cell

Antibodies

Study Results

No Results Posted as of Jul 15, 2022